Table 3.
Global success rates over the course of the study according to baseline APACHE II score, treatment strategy and septic shock status in modified intent-to-treat patients at the end of intravenous therapy (EOIVT), end of therapy (EOT), 2 weeks post-EOT and 6 weeks post-EOT
| EOIVT | EOT | 2 weeks post-EOT | 6 weeks post-EOT | |
|---|---|---|---|---|
| APACHE II ≤20a | ||||
| n (%) | 84/119 (70.6%) | 80/116 (69.0%) | 60/98 (61.2%) | 44/84 (52.4%) |
| 95% CI | 61.5–78.6% | 59.7–77.2% | 50.8–70.9% | 41.2–63.4% |
| APACHE II >20a | ||||
| n (%) | 27/38 (71.1%) | 27/38 (71.1%) | 17/30 (56.7%) | 11/25 (44.0%) |
| 95% CI | 54.1–84.6% | 54.1–84.6% | 37.4–74.5% | 24.4–65.1% |
| Switched to oral azolesb | ||||
| n (%) | 51/58 (87.9%) | 47/55 (85.5%) | 38/48 (79.2%) | 29/41 (70.7%) |
| 95% CI | 76.7–95.0% | 73.3–93.5% | 65.0–89.5% | 54.5–83.9% |
| IV anidulafungin onlyb | ||||
| n (%) | 60/99 (60.6%) | 60/99 (60.6%) | 39/80 (48.8%) | 26/68 (38.2%) |
| 95% CI | 50.3–70.3% | 50.3–70.3% | 37.4–60.2% | 26.7–50.8% |
| Septic shocka | ||||
| n (%) | 27/36 (75.0%) | 25/34 (73.5%) | 14/25 (56.0%) | 10/22 (45.5%) |
| 95% CI | 57.8–87.9% | 55.6–87.1% | 34.9–75.6% | 24.4–67.8% |
| No septic shocka | ||||
| n (%) | 84/121 (69.4%) | 82/120 (68.3%) | 63/103 (61.2%) | 45/87 (51.7%) |
| 95% CI | 60.4–77.5% | 59.2–76.5% | 51.1–70.6% | 40.8–62.6% |
Missing and unknown global or microbiological responses were excluded from these analyses.
a
Differences between global success rates were not statistically significant (p > 0.05) at any time-point.
b
Differences between global success rates were statistically significant (p < 0.05) at all time-points.